Rationale Melatonin modifies physiological and behavioral responses to psychostimulants, with the MT 1 and MT 2 melatonin receptors specifically implicated in facilitating methamphetamine (METH)-induced sensitization in melatoninproficient mice. Objective The objective of the study is to assess differences in locomotor sensitization after a single dose of methamphetamine in low-melatonin-expressing C57BL/6 wild-type and MT 1 receptor knockout (MT 1 KO) mice, comparing with melatonin-expressing C3H/HeN mice. Methods Mice received a vehicle or methamphetamine (1.2 mg/kg, i.p.) pretreatment (day 1) during the light (ZT5-9) or dark (ZT 19-21) periods in novel test arenas. Locomotor sensitization was assessed by methamphetamine challenge after an eight-day abstinence (day 9). TH protein expression was evaluated by immunofluorescence and Western blot analysis. Results Methamphetamine pretreatment induced statistically significant locomotor sensitization upon challenge after eightday abstinence in C3H and C57 wild-type mice during the light period. The magnitude of sensitization in C57 mice was diminished in the dark period and completely abrogated in MT 1 KO mice. No differences were observed in tyrosine hydroxylase immunoreactivity in the mesolimbic dopamine system. Additional exposures to the test arenas after methamphetamine pretreatment (nights 2-6) enhanced sensitization. Conclusions Deletion of the MT 1 melatonin receptor abolishes sensitization induced by a single METH pretreatment. The magnitude of sensitization is also altered by time of day and contextual cues. We conclude that the MT 1 melatonin receptor is emerging as a novel target of therapeutic intervention for drug abuse disorders.
Introduction
The MT 1 and MT 2 melatonin receptors mediate a myriad of physiological actions of the pineal hormone melatonin (Dubocovich et al. 2010) . Melatonin is synthesized and released according to a circadian rhythm with peak pineal and plasma levels at night, and as such, it is thought to be the principal agent signaling the duration of the dark phase of the 24 h day to peripheral tissues (Gillette and Mitchell 2002; Reiter 1991) . Melatonin signaling has been implicated in various responses triggered by drugs of abuse. Melatonin attenuates indicators of neurotoxicity in cell culture (Kongsuphol et al. 2009; Suwanjang et al. 2010) and animal model systems (Hirata et al. 1998; Itzhak et al. 1998; Kaewsuk et al. 2009) . At the behavioral level, responses to amphetamine and cocaine vary by time of day Gaytan et al. 1999) . Diurnal variations in cocaineinduced locomotor sensitization (Uz et al. 2003 ) and reward-seeking behavior ) are lost in melatonin-deficient pinealectomized mice. Further, work in our laboratory shows that genetic deletion of both MT 1 and MT 2 receptors prevents the development and expression of methamphetamine (METH)-induced locomotor sensitization in melatonin-proficient C3H/HeN mice (Hutchinson et al. 2012 ). Altogether, these data indicate that melatonin and its receptors play important roles in the modulation of behavioral responses by drugs of abuse, providing a new therapeutic target for drug-addiction-related disorders.
Locomotor sensitization is a form of behavioral plasticity in which early exposures to drugs of abuse increase the magnitude of later drug-stimulated locomotor responses (Hirabayashi and Alam 1981; Pierce and Kalivas 1997) . This phenomenon has been employed in rodents as a model for studying the neuroadaptations that occur during repeated drug exposures, because drug-stimulated locomotor responses are thought to be mediated by the same central dopaminergic pathways involved with motivation and incentive attribution (Wise and Bozarth 1987) . Locomotor sensitization is correlated with neurochemical sensitization of the dopaminergic pathways and with facilitated self-administration in rodent models (Addy et al. 2010; Vezina 2004) . Neuroadaptations in the dopaminergic pathway have been proposed to increase the "incentive salience" of the drug and drug-associated contextual cues, which is possibly associated with craving and compulsive drug seeking emblematic of addiction (Pierce and Kalivas 1997; Robinson and Berridge 2008) . Studies using this model have revealed modulation of sensitization by genetic alterations (Shen et al. 2010; Takino et al. 2009 ), time of day (Gaytan et al. 1999; Uz et al. 2002) , environmental context (Badiani et al. 1995a) , and adjunct drug treatments targeting a variety of receptors, channels, and transporters (Chiu et al. 2005; Futamura et al. 2010; Kurokawa et al. 2011) .
Reports on drug-induced sensitization have generally relied on experimental models wherein the effect of a drug is tested during and/or after a sequence of multiple intermittent administrations (Stewart and Badiani 1993) . There are, however, reports showing statistically significant increases in locomotor sensitization following a single pretreatment with cocaine (Kozanian et al. 2012; Valjent et al. 2010 ), amphetamine (Paz et al. 2011 , and METH (Kozanian et al. 2012; Nikaido et al. 2001) . As with sensitization paradigms based on repeated pretreatments, single-pretreatment locomotor sensitization is modified by contextual cues (Valjent et al. 2010 ) and pharmacological agents (Paz et al. 2011) . The use of a single pretreatment is potentially advantageous due to its circumvention of dependence-related phenomena that could confound the interpretation of behavioral assessments (Stewart and Badiani 1993; Valjent et al. 2010 ). Thus, a single psychostimulant treatment is sufficient to induce a state of sensitization that can be modified by experimental conditions and additional drug treatment.
In this study, we employed a single METH pretreatment to assess the functional role of the MT 1 melatonin receptor in locomotor sensitization expressed by C57BL/6 wild-type and MT 1 receptor knockout (MT 1 KO) mice. C57 mice were chosen for these experiments based on their genetic predisposition for null or greatly reduced pineal melatonin synthesis (Kasahara et al. 2010; Roseboom et al. 1998; von Gall et al. 2000) . C57 mice are endowed with mutations that markedly compromise melatonin synthesis: a point mutation/frameshift in the arylalkylamine N-acetyltransferase that converts serotonin to the intermediate N-acetylserotonin (Roseboom et al. 1998 ) and a truncation of the hydroxyindole-O-methyltransferase, which generates melatonin from N-acetylserotonin (Kasahara et al. 2010) . Focusing on these phenomena in a model system that combines a low/null-melatonin milieu with a targeted disruption of the MT 1 melatonin receptor allows for the assessment of ligand-independent MT 1 receptor function in locomotor sensitization, as this receptor exhibits constitutive activity (Browning et al. 2000; Ersahin et al. 2002; Roka et al. 1999; Soares et al. 2003) . This study demonstrated statistically significant MT 1 melatonin receptor-dependent locomotor sensitization in METH-pretreated C57 mice during the light period, with diminished magnitude during the dark period. We also found a diurnal variation in the magnitude of sensitization in C3H/HeN mice induced by a single METH pretreatment. The data suggest the MT 1 melatonin receptor in the C57 mice as the mediator of the sensitizing properties of METH after a single pretreatment.
Materials and methods

Animals
Male wild-type C3H/HeN (n=42) and C57BL/6 mice having wild-type or MT 1 KO genotypes (N=118) (Dubocovich et al. 2005) were bred in colonies maintained at the Laboratory Animal Facility of the University at Buffalo. Mice were bred under a 14-h:10-h light/dark cycle (150 to 200 lux during the daytime at the level of the cage) in a temperature-(22 ± 1°C) and humidity-controlled environment, with food and water provided ad libitum. Mice were switched to a 12/12 light/dark cycle at 6-12 weeks of age within ventilated and light-tight cabinets 10-14 days prior to experiments. The 12:12 light/dark cycle is traditionally used in rodent research paradigms (Faith and Huerkamp 2009) , and departures toward longer or shorter day lengths were found to increase neophobic behaviors in freely exploring C3H mice (Kopp et al. 1999) . Genotype was confirmed by PCR analysis of genomic DNA prepared from tail biopsies collected at weaning (3 weeks of age). All animal procedures were performed in accordance with the guidelines set forth by the National Institutes of Health and the Institutional Animal Care and Use Committee of the University at Buffalo.
Drugs
(+)-Methamphetamine hydrochloride was obtained from Sigma. Mice were randomly assigned to groups receiving either vehicle (saline, i.p.) or METH (1.2 or 2.4 mg/kg in saline, i.p.) during the pretreatment tests (day 1). METH (1.2 mg/kg) was administered to all mice during the challenge tests (days 9, 17, and 27). Saline was injected during habituation trials on days −3 to −1. METH doses were calculated in terms of the salt form of METH. All treatments were administered via intraperitoneal injections to deliver 0.01 ml solution per gram of mouse weight.
METH-induced sensitization test apparatus and protocol
Sensitization tests were conducted in 16 cylindrical (20 cm diameter × 20 cm height) Plexiglas arenas, the shape and size of which were shown to facilitate optimal expression of sensitization (Hirabayashi et al. 1991) . To assess sensitization after a single METH pretreatment, mice were first habituated to the arenas in three daily 2 h trials, wherein three saline injections were administered at the start (−60 min), midpoint (0 min), and end (60 min) of each test. During the pretreatment trial (day 1), VEH was given at the start (−60 min) and end (60 min) of the trial, with VEH or METH given to half the mice at the midpoint (0 min). We used multiple injections during each test to prevent timing-or cue-based learning associations that could confound data interpretation (Valjent et al. 2010) . The mice were minimally disturbed for eight days following the pretreatment test. The challenge test on day/night 9 was conducted by subjecting all mice to a sequence of VEH at the test start, METH at the midpoint, and VEH at the test end. Challenge tests on days 17 and 27 followed the same protocol. Sensitization after repeated pretreatments (Supplemental Figure 1 ) was assessed as described in Hutchinson et al. (2012) . For all locomotor tests, data were acquired by overhead camera imagery and digital video analysis by the LocoScan system (CleverSys, Reston, VA, USA). Light phase tests were conducted at Zeitgeber Time (ZT) 5-7 (lights on at ZT 0) with illumination of approximately 50 lux at the floor of the locomotor arena, and dark phase tests were conducted at ZT 19-21 in complete darkness with the aid of night-vision goggles and infrared light for camera imaging.
Tyrosine hydroxylase immunofluorescence
Mice were anesthetized with 0.24 ml/kg Avertin (1.4 %). Perfused transcardially at 5 mg/ml for 10 min with 0.9 % saline, followed by 20 min with 4 % paraformaldehyde in phosphatebuffered saline (PBS; 0.01 M, pH 7.4). Brains were dissected, post-fixed in 4 % paraformaldehyde for 4 h, and transferred to 30 % sucrose cryoprotectant for two days. Brains were embedded in optimal cutting temperature compound (Sakura Finetek, Torrance, CA, USA), frozen in 2-methylbutane on dry ice, and stored at −80°C. Sections (30 μm) containing caudateputamen (CPu) and nucleus accumbens (NAc) were taken from bregma 1.70 to 0.62 mm, and every sixth section (150 μm apart) was selected for analysis. Ventral tegmental area (VTA) sections were taken from bregma −2.92 to −3.88 mm, and every fourth section was selected for analysis.
Sections were washed and incubated with 1:1,000 mouse anti-tyrosine hydroxylase (TH) primary antibody (Millipore, Billerica, MA, USA) in PBS containing 0.5 % Triton X-100 and 1 % normal goat serum overnight at 4°C. Sections were stained with 1:1,000 Alexa Fluor 488 goat anti-mouse secondary antibody (Invitrogen, Carlesbad, CA, USA) for 90 min and coverslipped. Eight-bit images of CPu and NAc were acquired using a ×20 objective under a Nikon Eclipse fluorescence microscope (Nikon, Melville, NY, USA). VTA images were taken as mosaics (×20 objective) with a Zeiss Axio Observer Microscope equipped with automatic stage (Carl Zeiss AG, Oberkochen, Germany). ImageJ software (National Institute of Health) was used to evaluate the mean gray value of TH immunoreactivity in the CPu, NAc core, and NAc shell, where the TH protein in axon terminals produces a diffuse staining pattern. Background fluorescence was sampled in an unstained region and subtracted from CPu and NAc mean gray values. Labeled cell bodies were counted in VTA regions delineated by the investigator based on atlas coordinates (Paxinos and Franklin 2001) and TH fluorescence margins. All image analysis and quantification were done by an investigator blinded to genotype.
TH Western blot analysis
Brains were harvested from C57 WT (n=8) and MT 1 KO mice (n=8), and 1-mm sections were prepared on a slicer matrix (Zivic, Pittsburgh, PA, USA). CPu, NAc, and dopaminergic midbrain nuclei including VTA were collected as 1 mm punches, frozen on dry ice and stored at −80°C until analysis. The tissues were homogenized in lysis buffer containing 50 mM Tris-Cl pH 7.4, 150 mM NaCl, 1 % Triton X-100, and Complete Protease Inhibitor Cocktail (Roche Diagnostics, Atlanta, GA, USA). Samples containing 15-μg protein (determined using Bradford assay; Bio-Rad, Hercules, CA, USA) were subjected to SDS-PAGE (8 % acrylamide) and transferred to polyvinylidene difluoride membranes. Blots were incubated overnight at 4°C in either mouse anti-TH (1:1,000; Millipore, Temecula, CA, USA) or rabbit monoclonal anti-GAPDH (1:1,000; Cell Signaling, Boston, MA, USA) in TBST (20 mM Tris, 136 mM NaCl, and 0.1 % Tween-20) containing 5 % bovine serum albumin (BioRad, Hercules, CA, USA). Proteins were detected with 1:10,000 horseradish peroxidase (HRP)-conjugated goat anti-mouse (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or 1:10,000 HRPconjugated goat anti-rabbit (Jackson ImmunoResearch Laboratories, West Grove, PA, USA), followed by enhanced chemiluminescence (Thermo Scientific, Rockford, IL, USA). Bands at approximately 59 kDA (TH) and 37 kDa (GAPDH) were quantitated using Bio-Rad Quantity 1-D software.
Statistical analysis
Locomotor activity was assessed by distance traveled in 5 min and 1 h intervals. Time course data were analyzed by two-way mixed design analysis of variance (ANOVA) having the factors of pretreatment drug (VEH or METH) and time, followed by Bonferroni post hoc comparisons. Total activity before (−55 to 0 min) and after (5 to 60 min) the pretreatment/ challenge injection at 0 min was also calculated and analyzed by t-tests. Statistical results (F and p values) for locomotor time course analyses report the main effect of the drug pretreatment. Data from immunofluorescence and Western blot studies were analyzed by t-tests. Quantitative PCR data were analyzed by two-way ANOVA. All analyses were computed using GraphPad Prism v. 5.02 (GraphPad Software, Inc., La Jolla, CA, USA). For all analyses, p values < 0.05 were considered statistically significant.
Results
The goal of these studies was to assess the role of the MT 1 melatonin receptor in METH-induced sensitization in C57 mice with low/null melatonin levels. Sensitization was measured by challenge with a METH dose in C57 mice, after six daily METH pretreatments and five-day abstinence period. This protocol induced sensitization in the C3H/HeN mouse (Hutchinson et al. 2012) ; however, it did not develop or express locomotor sensitization in C57 WT mice (Supplemental Figure 1) . We then employed a single METH pretreatment protocol in a novel environment and challenged C3H mice after eight days (Fig. 1a) , which was previously used to induce cocaine-mediated sensitization in mice (Valjent et al. 2010) . During the light period at ZT 5-7, a single METH (1 mg/kg, i.p.) treatment on day 1 significantly increased locomotor activity (Fig. 1b) (F (1,14) =7.92, p < 0.05), and METH challenge on day 9 significantly expressed locomotor sensitization (Fig. 1c) (F (1,14) =4.95, p < 0.05). In contrast, the effect of METH pretreatment at ZT 19-21 was not significant on night 1 (Fig. 1d) (F (1,14) =5.62, p > 0.05), and locomotor sensitization was not expressed on night 9 (Fig. 1e)  (F (1,14) =2.31, p > 0.05).
We then proceeded to assess METH-induced sensitization in melatonin-deficient C57 mice using the single METH pretreatment protocol developed in the C3H mouse (Fig. 1) . METH pretreatment of C57 WT mice at ZT 5-7 significantly increased locomotor activity compared to VEH on day 1 (Fig. 2a) (F (1,22) =18.74, p < 0.05) and induced locomotor sensitization on day 9 (Fig. 2b) (F (1,22) =17.55, p < 0.05). During the dark period at ZT 19-21, METH pretreatment again triggered an enhanced locomotor response on night 1 (Fig. 2c) (F (1,14) =5.28, p < 0.05). METH challenge elicited a larger locomotor response in METH-pretreated mice at only the 5-and 10-min time points after METH challenge (Fig. 2d) (Bonferroni post hoc comparisons), indicating an overall reduction in the magnitude of sensitization compared to ZT 5-7.
To examine the temporal course of sensitization beyond day 9, C57 WT mice pretreated (day 1) and challenged (day 9) during the light phase of both groups were challenged again on days 17 and 27 (Fig. 3a) with METH. These studies were performed during the light phase based on the larger response observed at that time of day compared to the dark phase (see Fig. 2b, d) . Time course plots of the 2 h locomotor tests conducted during the pretreatment and challenge trials are shown in Fig. 3b , c. These data allow for within-groups comparisons evaluating the effect of successive METH challenges in mice first pretreated with VEH or METH. VEH-pretreated mice expressed larger locomotor responses on day 17 compared to day 9 and again on day 27 compared to day 17 (Bonferroni tests), revealing a sensitization effect induced by repeated METH challenges (Fig. 3b) . The METH-pretreated mice expressed a greater sensitization response on day 17 compared to day 9, but the response on day 27 was not statistically significantly larger than that on day 17 (p > 0.05) (Fig. 3c) . The total locomotor responses in 1 h test periods on days 9, 17, and 27 are shown in Fig. 3d to allow between-groups analysis of the effect of VEH and METH pretreatment at each sensitization test. Compared to VEH-pretreated controls, METHpretreated mice expressed a statistically significantly larger locomotor response to METH challenges on days 9 and 17, but not on day 27 (Fig. 3d) . These results show that METHinduced locomotor sensitization progressively increases after multiple challenges, each separated by 8-10 days. Furthermore, a saturation point is evident in the METH-pretreated mice by virtue of the statistically equivalent responses expressed after the second (day 17) and third (day 27) METH challenges.
We next addressed the effect of environmental context on the expression of locomotor sensitization during the dark phase. C57 WT mice were habituated and pretreated with VEH or METH at ZT 19-21 on night 1 and then placed in the testing arenas for 2 h periods for the dark phases of the next five days (nights 2-6) with no treatments (Fig. 4a) . METH-pretreated mice subjected to these arena trials expressed higher locomotor activity after the METH challenge compared to VEH-pretreated controls, indicating expression of sensitization (5-60 min) (Fig. 4b) (F (1,14) =7.71, p < 0.05). Interestingly, METH-pretreated mice subjected to the arena trials expressed higher locomotor activity (−55 to 0 min) before the METH challenge compared to VEHpretreated controls, suggesting a conditioned response to the arenas (Fig. 4b) . The arena trials increased the magnitude of METH-induced locomotor sensitization compared to mice that remained in the home cage for the entirety of the abstinence period (Fig. 4c) .
In MT 1 KO mice, METH pretreatment on day 1 triggered a significant locomotor effect compared to VEH at ZT 5-7 (Fig. 5a) (F (1,21) =21.18, p < 0.05). On day 9, the METHpretreated mice expressed greater locomotor activity prior to METH challenge, indicating a modest conditioned response induced by METH pretreatment (Fig. 5b, inset ) (t=2.16, df=21, p < 0.05). Responses to METH challenge were not significantly different between the pretreatment groups, indicating no expression of sensitization induced by METH pretreatment (Fig. 5b) (F (1,21) =1.70, p > 0.05). At ZT 19-21, METH pretreatment did not enhance the acute locomotor response in MT 1 KO mice on night 1 (Fig. 5c) (F (1,13) =0.65, p > 0.05), nor did it induce sensitization on day 9 (Fig 5d)  (F (1,13) =0.75, p > 0.05). Similarly, sensitization was not and then challenged with METH on day/night 9. The ordinates represent locomotor activity as distance traveled in 5-min intervals as a function of time (abscissae). The insets show the total distance traveled (m) from −55 to 0 min and from 5 to 60 min. Treatments were administered as denoted by arrows under the abscissae. *p < 0.05 compared to VEH observed in MT 1 KO mice even when the pretreatment dose was raised to 2.4 mg/kg (data not shown).
The differential expression of METH-induced locomotor sensitization between C57 WT and MT 1 KO mice could be attributed to a developmental defect in the mesolimbic dopamine pathways of the MT 1 KO mice. To address this question, we immunostained WT and MT 1 KO brain sections for TH, a marker of dopaminergic nerve terminals in the CPu and NAc, and of neuronal cell bodies in the VTA. Fluorescence imaging of the stained sections revealed a diffuse staining pattern consistent with TH expression in nerve terminals in the CPu and NAc. No significant genotype-associated differences in TH fluorescence intensity were found in the CPu, NAc core, and NAc shell (Supplemental Figure 2A-C and E-G) . Likewise, no significant differences were found between WT and MT 1 KO in the TH-positive cell density or overall size of the VTA (Supplemental Figure 2D and H) . TH protein levels determined by Western blot analysis were also unchanged between WT and MT 1 KO in the CPu (Supplemental Figure 3A) , NAc (Supplemental Figure 3B) , and midbrain nuclei including VTA and substantia nigra (Supplemental Figure 3C ).
Discussion
Locomotor sensitization has been widely used to evaluate the capacity of various treatments and genetic manipulations to alter the effects of psychostimulants. In this study, we employed locomotor sensitization to assess the role of the MT 1 melatonin receptor in low/null-melatonin-expressing C57 WT and MT 1 KO mice. We demonstrated a statistically significant locomotor sensitization to a METH challenge after eight days of withdrawal following a single METH pretreatment in both C3H and C57 mice. This is distinct from our observations using a repeated METH pretreatment sensitization protocol, wherein C57 mice express suppressed locomotor sensitization (Supplemental Figure 1) compared to C3H WT mice (Hutchinson et al. 2012) . The expression of sensitization after a single pretreatment was reduced during the dark phase in both C57 and C3H WT mice, which aligns with a report of suppressed cocaine-induced sensitization during the dark phase in C3H mice (Uz et al. 2003) . Locomotor sensitization was observed in both VEH-and METH-pretreated mice after repeated METH challenges, with the magnitude of the effect being significantly larger in METH-pretreated mice than in VEH-pretreated controls up to day 17 and with a ceiling effect encountered on day 27 in the METH-pretreated group after a total of four METH treatments. Sensitization was completely absent in C57 MT 1 KO mice during both light and dark phases even when tested at a higher pretreatment dose, which, to our knowledge, provides the first evidence of an obligate role for the MT 1 receptor in this process. The locomotor differences between the WT and MT 1 KO mice were probably not due to a developmental defect in the mesolimbic dopamine system, as TH immunoreactivity expression was Fig. 2 METH-induced locomotor sensitization in C57BL/6 WT mice during the light and dark phases. The ordinates represent locomotor activity as distance traveled in 5-min intervals as a function of time (abscissae). Mice were pretreated at either ZT 5-7 (a and b) or ZT 19-21 (c and d) with VEH (empty circles) or METH (1.2 mg/kg, i.p.) (filled squares) on day/night 1 and then challenged with METH on day/night 9. The insets show the total distance traveled (m) from −55 to 0 min and from 5 to 60 min. Treatments were administered as denoted by arrows under the abscissae. *p < 0.05 compared to VEH not different in the CPu, NAc, and VTA between the C57 WT and MT 1 KO mice. Exposure to the locomotor arenas in the dark phase during abstinence enhanced the magnitude of sensitization in METH-pretreated C57 WT mice, supporting a role for contextual cues in modulating the sensitized response. In showing a crucial role for the MT 1 melatonin receptor in METH-induced locomotor sensitization, our findings expand upon prior studies which report alterations in psychostimulantinduced effects by exogenous and/or pineal gland function (Hirata et al. 1998; Kaewsuk et al. 2009; Kongsuphol et al. 2009; Kurtuncu et al. 2004) .
Deletion of the MT 1 receptor alone blocked sensitization during the light phase in C57 mice but not in C3H mice (Hutchinson et al. 2012) . The basal locomotor responses of VEH-pretreated WT and MT 1 KO mice on day 1 during both light and dark phases are not significantly different, suggesting that the locomotor output systems of the two genotypes are equivalent and not affected by nonspecific developmental compensation (Crusio et al. 2009 ). With the caveat that the C3H and C57 mice have numerous genetic differences, the complete loss of sensitization in C57 MT 1 KO mice as compared to the WT may be related to the levels of endogenous melatonin, as C57 mice have been regarded as a mouse model of melatonin deficiency (Torres-Farfan et al. 2006; Uz et al. 2002) . The MT 1 receptor expresses considerable ligand-independent activity in human recombinant cell culture models (Browning et al. 2000; Roka et al. 1999) , in rat caudal artery (Ersahin et al. 2002) , and in rat ovary (Soares et al. 2003) . The presence of constitutively active MT 1 melatonin receptors may facilitate METH-induced sensitization in WT mice, suggesting that MT 1 receptor activity, rather than expression, is required for the induction of sensitization in C57 mice. Alternatively, very low levels of endogenous melatonin expressing high affinity binding for the MT 1 receptor may maintain persistent receptor signaling and mediate locomotor sensitization in WT mice (Dubocovich et al. 2010 ). Von Gall et al. (2000 showed that C57BL mice may actually produce extremely low levels of endogenous melatonin in the pineal gland. Rhythmicity of melatonin synthesis was not found, but may be difficult to determine in C57 mice on account of the melatonin levels being very near the limit of detection of the assay used (von Gall et al. 2000) . Even considering the plethora of genetic differences between C3H and C57 mice, the relative contributions of constitutive receptor activity and/or persistent activation of the MT 1 melatonin receptor by endogenous melatonin may facilitate METH-induced sensitization.
The optimizing effect of context and environmental novelty on the expression of locomotor sensitization is well-established in the literature (Badiani et al. 1995a; Badiani et al. 1995b) . In attempting to address the effects of context and novelty, we Graphs show serial time course traces for a group of C57 WT mice pretreated with VEH on day 1 and challenged with METH on days 9, 17, and 27, and a group of mice pretreated with METH on day 1 and challenged with METH on days 9, 17, and 27. The statistical significance of the difference among test days is shown in the upper right of graphs. *p < 0.05 compared to day 1; #p < 0.05 compared to day 9; †p < 0.05 compared to day 17. Panel d shows direct comparisons between VEH-and METH-pretreated mice on each challenge test day. The ordinate represents the mean±SEM distance traveled from 0 to 60 min. *p < 0.05 compared to VEH pretreatment found that the additional arena trials augmented the expression of sensitization in METH-pretreated C57 mice during the dark phase, which had been suppressed in mice that remained in the home cage for the abstinence period (see Fig. 1 ). It is noteworthy that the mice expressed increased locomotor activity during the hour prior to METH challenge after repeated arena trials, an effect not observed in mice maintained in home cages during abstinence. This observation suggests an effect of conditioned hyperactivity, wherein contexts paired with a drug take on the ability to increase locomotor activity in a drug-free state. Conditioned hyperactivity has been reported to arise from METH treatment in Sprague-Dawley rats (Bevins and Peterson 2004) , in Swiss Webster mice (Rauhut and Bialecki 2011) , and in C57 mice (Orsini et al. 2004) . In the present study, the arena trials during abstinence may have repeatedly reactivated and reconsolidated the memory of METH treatment and strengthened the Pavlovian pairing between drug and context (Dudai 2006) . We postulate that the positive effect of the arena trials on the expression of sensitization after METH challenge during the dark phase may arise from the conditioned hyperactivity effect bolstering the sensitization effect.
Psychostimulant treatments modulate the expression of clock gene period 1 (Per1), a clock gene whose expression oscillates with a 24 h period in tissues throughout the brain and periphery (Falcon and McClung 2009 ). Per1 protein levels are highest in the NAc and CPu during the light phase compared to dark (Uz et al. 2003) , and this pattern correlates directly with diurnal variations in locomotor sensitization induced by cocaine (Abarca et al. 2002) and by METH (Uz et al. 2003) . METH increases Per1 mRNA expression 1 h after a 5 mg/kg treatment (Nikaido et al. 2001) , and the same dose of METH sensitizes Per1 mRNA induction triggered by a 0.5-mg/kg challenge seven days later (Nikaido et al. 2001) . Rhythmic diurnal expression of Per1 is lost in mice lacking the MT 1 receptors, indicating a requirement of this receptor for normal Per1 gene function (Imbesi et al. 2009 ). In the present studies, METH-induced sensitization after a single pretreatment was stronger during the light phase compared to the dark phase in WT mice and was lost completely at both times of the day in MT 1 KO mice. Thus, it is likely that the magnitude of METH-induced locomotor sensitization during the light and dark phases is correlated with rhythmic Per1 expression in our C3H and C57 mice. A hypothesis for further investigation would propose the induction of sensitization facilitated by high Per1 levels through constitutively active MT 1 receptors during the light phase and attenuated sensitization responses during the dark phase when Per1 protein levels are relatively low.
Our studies exploit the effect of locomotor sensitization to show variations in METH responsiveness caused by removal of the MT 1 melatonin receptor, by testing at different times of day, and by additional exposures to the drug-paired environment. Perhaps most importantly, our results illustrate the ability of the MT 1 receptor to modulate the development and expression of METH-induced locomotor sensitization. Blockade of the MT 1 receptor by selective competitive antagonists would be expected to attenuate the sensitizing effects of METH, which are associated with neurobiological changes leading to addiction (Pierce and Kalivas 1997; Robinson and Berridge 2008) . The discovery and use of novel MT 1 receptor antagonists could open the possibility of new therapeutics capable of remediating symptoms arising from METH abuse.
